Drug class
Ophthalmic Carbonic Anhydrase Inhibitors
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure. Read more about Ophthalmic Carbonic Anhydrase Inhibitors
47 drugs in this class 22 manufacturers
Drugs in Ophthalmic Carbonic Anhydrase Inhibitors
DORZOLAMIDE-TIMOLOL (dorzolamide HCl/timolol maleate)
COSOPT (dorzolamide HCl/timolol maleate)
COSOPT (PF) (dorzolamide HCl/timolol maleate/PF)
AZOPT (brinzolamide)
DORZOLAMIDE HCL
DORZOLAMIDE HCL
DORZOLAMIDE-TIMOLOL (dorzolamide HCl/timolol maleate)
DORZOLAMIDE-TIMOLOL (dorzolamide HCl/timolol maleate/PF)
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure.
They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport.
Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents.
By delivering targeted local enzyme inhibition, they minimize many of the systemic adverse effects traditionally associated with oral carbonic anhydrase inhibitors while mitigating the risk of progressive glaucomatous optic nerve damage.
-
nih.gov
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents
-
nih.gov
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents
-
nih.gov
Ophthalmic carbonic anhydrase inhibitors are a class of topical ocular medications, including dorzolamide and brinzolamide, used to reduce intraocular pressure
-
fda.gov
They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport
-
pharmacytimes.com
They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport
-
nih.gov
They function by inhibiting the enzyme carbonic anhydrase within the ciliary body epithelium, which slows bicarbonate ion synthesis and subsequently decreases aqueous humor production and fluid transport
-
nih.gov
Therapeutically, these agents are primarily indicated for the management of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, either as monotherapy or as adjunctive therapy with other intraocular pressure-lowering agents
-
nih.gov
By delivering targeted local enzyme inhibition, they minimize many of the systemic adverse effects traditionally associated with oral carbonic anhydrase inhibitors while mitigating the risk of progressive glaucomatous optic nerve damage
-
nih.gov
By delivering targeted local enzyme inhibition, they minimize many of the systemic adverse effects traditionally associated with oral carbonic anhydrase inhibitors while mitigating the risk of progressive glaucomatous optic nerve damage
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.